Ignacio José Calomarde Heras, Francisco Milán Cabrera, Alberto Villarrubia de Juan, Miguel Ángel De Frutos Carro, UAV ...

A 4D Molecular Therapeutics, Inc. phase 2 PRISM study indicated that there was an 89% reduction in annualized injections when Wet-AMD patients were given a high dose of 4D-150; Phase 3 trial ...

Entered strategic partnership with Otsuka Pharmaceutical Co., Ltd. for the development and commercialization of 4D-150 in the APAC region; to ...

4D Molecular Therapeutics announced an acceleration in the timeline for its 4FRONT-1 Phase 3 trial data readout of the 4D-150 treatment for wet age-related macular degeneration (AMD), now expected in ...

In the latest quarter, 4 analysts provided ratings for 4D Molecular Therapeutics (NASDAQ:FDMT), showcasing a mix of bullish and bearish perspectives. The table below provides a concise overview of ...

TOKYO and EMERYVILLE, Calif., July 10, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503) (President and CEO: Naoki Okamura, "Astellas") and 4D Molecular Therapeutics, Inc. (FDMT) (CEO: David Kirn, ...

D Molecular Therapeutics, Inc. ( ($FDMT) ) has released its Q3 earnings. Here is a breakdown of the information 4D Molecular Therapeutics, Inc.

SAN FRANCISCO--(BUSINESS WIRE)--4D Molecular Therapeutics (4DMT), a leader in next-generation gene therapy vector discovery and product development, today announced a collaboration and license ...

Please provide your email address to receive an email when new articles are posted on . Astellas has gained the rights to utilize 4DMT’s R100 vector to deliver its unique genetic payloads. Astellas is ...